BIOGEN INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOGEN INC. stock issued during period, value, employee stock purchase plan for fiscal 2014 was $46.40M, a 19.90% increase from fiscal 2013.
- BIOGEN INC. stock issued during period, value, employee stock purchase plan for fiscal 2013 was $38.70M, a 34.84% increase from fiscal 2012.
- BIOGEN INC. stock issued during period, value, employee stock purchase plan for fiscal 2012 was $28.70M, a 25.88% increase from fiscal 2011.
- BIOGEN INC. stock issued during period, value, employee stock purchase plan for fiscal 2011 was $22.80M, a 2.98% decline from fiscal 2010.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2014-12-31 | $46.40M 10-K · filed 2015-02-04 | |
| 2013-12-31 | $38.70M 10-K · filed 2015-02-04 | |
| 2012-12-31 | $28.70M 10-K · filed 2015-02-04 | |
| 2011-12-31 | $22.80M 10-K · filed 2014-02-06 | |
| 2010-12-31 | $23.50M 10-K · filed 2013-02-05 | |
| 2009-12-31 | $22.60M 10-K · filed 2012-02-03 | |
| 2008-12-31 | $21.30M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |